# Cencora, Inc.: Form 10-Q for the period ended Jun 30, 2009

- Company: [Cencora, Inc.](/companies/cor.md) (CIK 1140859)
- Form: 10-Q
- Filed: 2009-08-06
- Accepted by EDGAR: Aug 6, 2009, 14:14 ET
- Period: 2009-06-30
- Accession: 0000950123-09-030790
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1140859/000095012309030790/c88560e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1140859/000095012309030790/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2009-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2009-04-01 to 2009-06-30 | $18.39bn | us-gaap:Revenues |
| Revenue | 9 months, 2008-10-01 to 2009-06-30 | $53.04bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2009-04-01 to 2009-06-30 | $17.87bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2008-10-01 to 2009-06-30 | $51.48bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2009-04-01 to 2009-06-30 | $519.2m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2008-10-01 to 2009-06-30 | $1.56bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2009-04-01 to 2009-06-30 | $277.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2008-10-01 to 2009-06-30 | $828.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2009-04-01 to 2009-06-30 | $213.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2008-10-01 to 2009-06-30 | $659.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2009-04-01 to 2009-06-30 | $73.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2008-10-01 to 2009-06-30 | $233.0m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2009-04-01 to 2009-06-30 | $0.40 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2008-10-01 to 2009-06-30 | $1.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2009-04-01 to 2009-06-30 | $0.40 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2008-10-01 to 2009-06-30 | $1.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2009-04-01 to 2009-06-30 | 300,592,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2008-10-01 to 2009-06-30 | 305,171,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2008-10-01 to 2009-06-30 | $430.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2008-10-01 to 2009-06-30 | $102.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2008-10-01 to 2009-06-30 | $45.9m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2008-10-01 to 2009-06-30 | $273.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2009-06-30 | $912.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2009-06-30 | $9.14bn | us-gaap:AssetsCurrent |
| Total assets | at 2009-06-30 | $12.74bn | us-gaap:Assets |
| Current liabilities | at 2009-06-30 | $8.59bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2009-06-30 | $1.19bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2009-06-30 | $710.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2009-06-30 | $2.78bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 6,693 characters.

We continue to expect that our total revenue growth in fiscal 2009 will be between 1% and 3%, with ABDC growing between 0% and 2% and ABSG growing between 5% and 7% for the fiscal year. ABDC’s revenue growth is expected to be higher in the quarter ending September 30, 2009, in comparison to its revenue growth in the first nine months of fiscal 2009 due to the anniversary of the national retail drug chain customer loss described above and the addition of several new customers in the second half of fiscal 2009. The expected growth also reflects U.S. pharmaceutical industry conditions, including increases in prescription drug utilization, the introduction of new products, and higher branded pharmaceutical prices, offset, in part, by the increased use of lower-priced generics. Our growth has also been impacted by industry competition and changes in customer mix. Industry sales in the United States, as recently estimated by industry data firm IMS Healthcare, Inc. (“IMS”), are expected to contract between 1% and 2% in 2009 and are expected to be flat over the five-year period ending 2013 due to continued brand to generic conversions as well as the economic slowdown in the United States in 2009. IMS expects that certain sectors of the market, such as biotechnology and other specialty and generic pharmaceuticals will grow faster than the overall market. Our future revenue growth will continue to be affected by various factors such as: industry growth trends, including the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand manufacturers, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on reimbursement rates, and changes in Federal government rules and regulations.

Gross profit of $519.2 million in the quarter ended June 30, 2009 increased 4% from the prior year quarter. As a percentage of total revenue, gross profit in the quarter ended June 30, 2009 was 2.82%, an increase of 5 basis points from the prior year quarter. These increases were primarily due to the strong growth and increased profitability of our generic programs (with generic revenue increasing by 23% in comparison to the prior year quarter), increased contributions from our fee-for-service agreements with branded manufacturers, and higher brand-name manufacturer price appreciation. All of these positive factors combined to more than offset normal competitive pressures on customer margins in the current year quarter. Gross profit in the prior year quarter was impacted by an $8.4 million inventory write-down of certain pharmacy dispensing equipment. Gross profit of $1.6 billion in the nine months ended June 30, 2009 increased 3% from the prior year period. As a percentage of total revenue, gross profit in the nine months ended June 30, 2009 was 2.94%, an increase of 7 basis points from the prior year period. These increases were primarily due to the strong growth and increased profitability of our generic programs; increased contributions from our fee-for-service agreements, including $10.2 million of fees relating to prior period sales due to the execution of new agreements in the quarter ended December 31, 2008; and good growth from ABSG’s businesses, all of which were partially offset by ABSG’s $12.7 million loss on its influenza vaccine program, which included a $15.5 million write-down of excess influenza vaccine inventory, and normal competitive pressures on customer margins in the current nine-month period. Gross profit in the current year nine-month period benefited from a settlement of $1.8 million with a former customer. Gross profit in the prior year nine-month period benefited from a gain of $13.2 million relating to favorable litigation settlements with a former customer and a major competitor, and was partially offset by the above-mentioned $8.4 million inventory write-down. Additionally, in the prior year nine-month period, we recognized a gain of $1.6 million from antitrust litigation settlements with pharmaceutical manufacturers. This gain, which was excluded from the determination of Pharmaceutical Distribution segment’s gross profit, was recorded as reduction to cost of goods sold.

Our cost of goods sold for interim periods includes a last-in, first-out (“LIFO”) provision that is based on our estimated annual LIFO provision. We recorded a LIFO charge of $4.1 million and $5.0 million in the quarters ended June 30, 2009 and 2008, respectively. Our LIFO charge was $20.8 million and $17.7 million in the nine months ended June 30, 2009 and 2008, respectively. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences.

Operating expenses of $306.2 million and $902.4 million in the quarter and nine months ended June 30, 2009, increased by 2% and 1%, respectively, from the prior year periods. Operating expenses in the quarter ended June 30, 2009 increased from the prior year quarter due to an intangible asset impairment of $8.9 million, a legal accrual of $3.0 million relating to the OMH matter (see Note 9 to the Consolidated Financial Statements), and an increase in bad debt expense of $4.1 million, all of which was offset in part, by a reduction in facility consolidations, employee severance and other of $7.7 million from the prior year quarter. Operating expenses in the nine months ended June 30, 2009 increased from the prior year period due to an increase in bad debt expense of $11.6 million and an increase in asset impairment charges of $8.3 million, offset in part, by a decrease in depreciation and amortization expenses of $5.5 million and a decrease in facility consolidations, employee severance and other charges of $3.9 million. Additionally, expenses incurred in connection with our Business Transformation project, which includes a new enterprise resource planning (“ERP”) platform, increased by $16.0 million from the prior year period. As a result of our cE2 initiative described below, we have been able to substantially offset these incremental costs by reducing our warehouse operating costs through continuing productivity improvements and by streamlining our organizational structures within ABDC and ABSG. As a percentage of total revenue, operating expenses were 1.66% and 1.70% in the quarter and nine months ended June 30, 2009; this compared to 1.67% and 1.69% in the prior year periods.

## Market risk

As filed, 168 characters.

The Company’s most significant market risk is the effect of fluctuations in interest rates. See discussion under “Liquidity and Capital Resources” in Item 2 on page 32.

## Controls and procedures

As filed, 1,322 characters.

### Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company’s reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The Company’s Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company’s disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

There were no changes during the fiscal quarter ended June 30, 2009 in the Company’s internal control over financial reporting that materially affected, or are reasonably likely to materially affect, those controls.

## Risk factors

As filed, 2,390 characters.

The Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2008 included a detailed discussion of our risk factors under Part I, “Item 1A — Risk Factors.” The information presented below sets forth material changes from the risk factors described in the 2008 Form 10-K and should be read in conjunction with the risk factors and information described in the 2008 Form 10-K and the Company’s filings with the SEC since the date of the 2008 Form 10-K.

*The enactment of provincial legislation or regulations in Canada to lower pharmaceutical product pricing and service fees may adversely affect our pharmaceutical distribution business in Canada, including the profitability of that business.*

As in the United States, our products and services function within the existing regulatory structure of the healthcare system in Canada. The purchase of pharmaceutical products in Canada is funded in part by the provincial governments, which each regulate the financing and reimbursement of drugs independently. In recent years, like the United States, the Canadian healthcare industry has undergone significant changes in an effort to reduce costs and government spending. For example, in 2006, the Ontario government enacted the Transparent Drug System for Patients Act, which significantly revised the drug distribution system in Ontario. Then in July 2009, the Ontario government announced that it was undertaking a review of that legislation with a view to, among other things, lower costs for taxpayers. Some of these potential changes, such as adverse changes in legislation or regulations governing the drug distribution supply chain, prescription drug pricing, healthcare services or mandated benefits or a reduction in government funding for certain healthcare services may result in lower service fees, cause healthcare industry participants to reduce the amount of our products and services they purchase or the price they are willing to pay for our products and services. Legislation and/or regulations that may lower pharmaceutical product pricing and service fees are reportedly under consideration by some other provinces as well. We expect continued government and private payor pressure to reduce pharmaceutical pricing. Changes in pharmaceutical manufacturers’ pricing or distribution policies could also significantly reduce our profitability in Canada.

Filed Aug 6, 2009.
Source: SEC EDGAR, the filing index for accession 0000950123-09-030790. Last ingested by Listed: Nov 15, 2026, 01:23 ET. No prices; not investment advice.
